doi: 10.1091/mbc.E15-10-0698.
Exploiting DNA repair defects for novel cancer therapies
Affiliations
- PMID: 27418635
- PMCID: PMC4945134
- DOI: 10.1091/mbc.E15-10-0698
Item in Clipboard
Exploiting DNA repair defects for novel cancer therapies
Mol Biol Cell.
.
Abstract
Most human tumors accumulate a multitude of genetic changes due to defects in the DNA damage response. Recently, small-molecule inhibitors have been developed that target cells with specific DNA repair defects, providing hope for precision treatment of such tumors. Here we discuss the rationale behind these therapies and how an important bottleneck-patient selection-can be approached.
© 2016 van Gent and Kanaar. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).
Similar articles
-
DNA Double Strand Break Repair - Related Synthetic Lethality.Curr Med Chem. 2019;26(8):1446-1482. doi: 10.2174/0929867325666180201114306. Curr Med Chem. 2019. PMID: 29421999 Review.
-
DNA Repair.Recent Results Cancer Res. 2016;198:1-24. doi: 10.1007/978-3-662-49651-0_1. Recent Results Cancer Res. 2016. PMID: 27318679 Review.
-
Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.Clin Cancer Res. 2009 Oct 15;15(20):6314-20. doi: 10.1158/1078-0432.CCR-09-0096. Epub 2009 Oct 6. Clin Cancer Res. 2009. PMID: 19808869 Review.
-
YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.Mol Cancer Res. 2015 Oct;13(10):1389-97. doi: 10.1158/1541-7786.MCR-15-0036. Epub 2015 Jun 26. Mol Cancer Res. 2015. PMID: 26116172 Free PMC article.
-
Targeting the DNA damage response for cancer therapy.DNA Repair (Amst). 2009 Sep 2;8(9):1153-65. doi: 10.1016/j.dnarep.2009.04.011. Epub 2009 Jun 5. DNA Repair (Amst). 2009. PMID: 19501553 Review.
Cited by
-
The SWI/SNF ATPase BRG1 stimulates DNA end resection and homologous recombination by reducing nucleosome density at DNA double strand breaks and by promoting the recruitment of the CtIP nuclease.Cell Cycle. 2020 Nov;19(22):3096-3114. doi: 10.1080/15384101.2020.1831256. Epub 2020 Oct 12. Cell Cycle. 2020. PMID: 33044911 Free PMC article.
-
A network-pathway based module identification for predicting the prognosis of ovarian cancer patients.J Ovarian Res. 2016 Nov 2;9(1):73. doi: 10.1186/s13048-016-0285-0. J Ovarian Res. 2016. PMID: 27806724 Free PMC article.
-
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.BMC Urol. 2019 May 6;19(1):33. doi: 10.1186/s12894-019-0453-9. BMC Urol. 2019. PMID: 31060606 Free PMC article.
-
MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER+ Breast Cancer.Cells. 2023 Jul 25;12(15):1929. doi: 10.3390/cells12151929. Cells. 2023. PMID: 37566008 Free PMC article.
-
Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.Cancer Med. 2018 Nov;7(11):5665-5678. doi: 10.1002/cam4.1816. Epub 2018 Oct 18. Cancer Med. 2018. PMID: 30334367 Free PMC article.
References
-
- Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene. 2010;29:6085–6098. - PubMed
-
- Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, Karalis K, Kim HJ, MacQueen L, Mahmoodian R, et al. Engineered in vitro disease models. Annu Rev Pathol. 2015;10:195–262. - PubMed
-
- Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
